Patents by Inventor Andrew Oberst

Andrew Oberst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED CELL DEATH-INDUCING ENZYMES AND METHODS OF USE
    Publication number: 20210040469
    Abstract: The disclosure provides compositions and methods for inducing programmed cell death, such as necroptosis. Compositions may comprise fusion proteins comprising a death inducing domain and a multimerization domain; nucleic acids encoding fusion proteins; and cells comprising fusion proteins. The compositions may be used in methods such as cancer therapy, including in combination with additional immunotherapeutics.
    Type: Application
    Filed: January 24, 2019
    Publication date: February 11, 2021
    Applicant: University of Washington
    Inventors: Andrew Oberst, Nicholas Hubbard, Annelise Snyder
  • Truncated Constructs Related To RIPK3
    Publication number: 20190119656
    Abstract: The invention provides methods and compositions for inducing necroptosis in target cells, including for example cancer cells. This invention provides compositions and methods for the controlled expression and formation of full length RDPK3 homodimers, truncated RTPK3 oligomers and/or full length RIPK3/RIPK1 heterodimers in target cells both in vitro and in vivo therapeutic and research applications.
    Type: Application
    Filed: September 24, 2018
    Publication date: April 25, 2019
    Inventors: Douglas Green, Andrew Oberst
  • Truncated Constructs of RIPK3 and Related Uses
    Publication number: 20160160189
    Abstract: The invention provides methods and compositions for inducing necroptosis in target cells, including for example cancer cells. This invention provides compositions and methods for the controlled expression and formation of full length RDPK3 homodimers, truncated RTPK3 oligomers and/or full length RIPK3/RIPK1 heterodimers in target cells both in vitro and in vivo therapeutic and research applications.
    Type: Application
    Filed: April 30, 2014
    Publication date: June 9, 2016
    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Douglas Green, Andrew Oberst